Cargando…
Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma
OBJECTIVE: Several anti-programmed cell death 1 (anti-PD-1) antibodies have demonstrated potential efficacy in the treatment of advanced esophageal squamous cell cancer (ESCC). However, the response to subsequent chemotherapy after the failure of PD-1 blockade in ESCC patients has not been reported,...
Autores principales: | Zhang, Bo, Wang, Xi, Li, Qun, Mo, Hongnan, Wang, Xingyuan, Song, Yan, Xu, Jianping, Qu, Tao, Huang, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955162/ https://www.ncbi.nlm.nih.gov/pubmed/31949393 http://dx.doi.org/10.21147/j.issn.1000-9604.2019.06.07 |
Ejemplares similares
-
Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma
por: Liu, Yun, et al.
Publicado: (2021) -
Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody
por: Wang, Xi, et al.
Publicado: (2019) -
Safety, anti-tumour activity, and pharmacokinetics of
fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a
dose-escalation, phase 1 study
por: Mo, Hongnan, et al.
Publicado: (2018) -
SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
por: Mu, Lan, et al.
Publicado: (2021) -
Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
por: Liu, Min, et al.
Publicado: (2020)